Effects of celecoxib and nordihydroguaiaretic acid on puromycin aminonucleoside-induced nephrosis in the rat

Journal of Korean Medical Science

Volumn 24, Issue SUPPL.1, 2009, Pages

  Lee, Dong Won ^a   Kwak, Ihm Soo ^a   Lee, Soo Bong ^a   Song, Sang Heon ^a   Seong, Eun Young ^a   Chung, Hyun Chul ^b   Yang, Byeong Yun ^a   Lee, Min Young ^a   Sol, Mee Young ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Ulsan University College of Medicine   (South Korea)

Author keywords

Celecoxib; Nordihydroguaiaretic acid; Proteinuria; Puromycin aminonucleoside

Indexed keywords

CELECOXIB; CREATININE; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PROSTAGLANDIN SYNTHASE INHIBITOR; PUROMYCIN AMINONUCLEOSIDE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; ELECTRON MICROSCOPY; MALE; METABOLISM; NEPHROSIS; PODOCYTE; RAT; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; CREATININE; CYCLOOXYGENASE INHIBITORS; MALE; MICROSCOPY, ELECTRON; NEPHROSIS; NORDIHYDROGUAIARETIC ACID; PODOCYTES; PUROMYCIN AMINONUCLEOSIDE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TIME FACTORS;

EID: 62449191096     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.S1.S183     Document Type: Article

References (29)

1. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-47.
2. Mahan JD, Sisson RS, Vernier RL. Glomerular basement membrane anionic charge site change early in aminonucleoside nephrosis. Am J Pathol 1986; 125: 393-401.
3. Furness PN, Turner DR, Cotton RE. Basement membrane charge in human glomerular disease. J Pathol 1986; 150: 267-78.
4. Washizawa K, Kasai S, Mori T, Komiyama A, Shigematsu H. Ultrastructural alteration of glomerular anionic sites in nephrotic patients. Pediatr Nephrol 1993; 7: 1-5.
5. Blume C, Heise G, Mhlfeld A, Bach D, Schrr K, Gerhardz CD, Grabensee B, Heering P. Effects of flosulide, a selective cyclooxygenase 2 inhibitor, on passive Heymann nephritis in the rat. Kidney Int 1999; 56: 1770-8.
6. Emery P, Vane J, Botting J, Botting R, eds. Pharmacology, safety data and therapeutics of COX-2 inhibitors, in improved non-steroidal anti-inflammatory drugs, COX-2 enzyme inhibitors, Hingham, MA: Kluwer, 1996; 229-41.
7. Arteaga S, Andrade-Cetto A, Crdenas R. Larrea tridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. J Ethnopharmacol 2005; 98: 231-9.
8. Tries S, Laufer S, Radziwon P, Breddin HK. Antithrombotic and platelet function inhibiting effects of ML3000, a new anti-inflammatory drug with COX/5-LOX inhibitory activity. Inflamm Res 2002; 51: 129-34.
9. Salari H, Braquet P, Borgeat P. Comparative effects of indomethacin, acetylenic acids, 15-HETE, NDGA and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets. Prostaglandins Leukot Med 1984; 13: 53-60.
10. Anjaneyulu M, Chopra K. Nordihydroguairetic acid, a lignin prevents oxidative stress and the development of diabetic nephropathy in rats. Pharmacology 2004; 72: 42-50.
11. Frenk S, Antonowicz I, Craig JM, Metcoff J. Experimental nephrotic syndrome induced in rats by aminonucleoside. Renal lesion and body electrolyte composition. Proc Soc Exp Biol Med 1955; 89: 424-7.
12. Fishman JA, Karnovsky MJ. Effects of the aminonucleoside: puromycin on glomerular epithelial cells in vitro. Am J Pathol 1985; 118: 398-407.
13. Bertram JF, Messina A, Ryan GB. In vitro effects of puromycin aminonucleoside on the ultrastructure of rat glomerular podocytes. Cell Tissue Res 1990; 260: 555-63.
14. Farquhar MG, Palade GE. Glomerular permeability: II. ferritin transfer across the glomerular capillary wall in nephrotic rats. J Exp Med 1961; 114: 699-716.
15. Furness PN, Harris K. An evaluation of experimental models of glomerulonephritis. Int J Exp Pathol 1994; 75: 9-22.
16. Grond J, Weening JJ, Elema JD. Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside. Lab Invest 1984; 51: 277-85.
17. Marinides GN, Groggel GC, Cohen AH, Border WA. Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. Kidney Int 1990; 37: 749-57.
18. Liu S, Li Y, Zhao H, Chen D, Huang Q, Wang S, Zou W, Zhang Y, Li X, Huang H. Increase in extracellular cross-linking by tissue transglutaminase and reduction in expression of MMP-9 contribute differentially to focal segmental glomerulosclerosis in rats. Mol Cell Biochem 2006; 284: 9-17.
19. Hagiwara M, Yamagata K, Capaldi RA, Koyama A. Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis. Kidney Int 2006; 69: 1146-52.
20. Wang JL, Cheng HF, Zhang MZ, McKanna JA, Harris RC. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 1998; 275: F613-22.
21. Wang JL, Cheng HF, Shappell S, Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000; 57: 2334-42.
22. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002; 62: 929-39.
23. Ezberci F, Tekin E, Onuk E. Protective effect of a lipoxygenase inhibitor, nordihydroguaiaretic acid, on the ileal motor disturbances induced by Serratia marcescens endotoxin in rats. Surg Today 2001; 31: 497-501.
24. Kollman-Bauerly KA, Thomas DL, Adrian TE, Lien EL, Vanderhoof JA. The role of eicosanoids in the process of adaptation following massive bowel resection in the rat. JPEN J Parenter Enteral Nutr 2001; 25: 275-81.
25. Marchenko HI, Kotsiuruba VM, Butovych IA, Sorochyns'kyi AE, Zrazhevs'ka VK, Tumanovs'ka LV. The correction of disorders in arachidonic acid metabolism in coronary spasm of an immune origin. Frziol Zh 1994; 40: 81-7.
26. Cheng H, Wang S, Jo YI, Hao CM, Zhang M, Fan X, Kennedy C, Breyer MD, Moeckel GW, Harris RC. Overexpression of cyclooxygenase -2 predispodes to podocyte injury. J Am Soc Nephrol 2007; 18: 551-9.
27. Poncelet AC, Schnaper HW. Regulation of human mesangial cell collagen expression by transforming growth factor-β1. Am J Physiol 1998; 275: F458-66.
28. Suzuki S, Ebihara I, Tomino Y, Koide H. Transcriptional activation of matrix genes by transforming growth factor-beta 1 in mesangial cells. Exp Nephrol 1993; 1: 229-37.
29. McKay NG, Khong TF, Haites NE, Power DA. The effects of transforming growth factor-beta 1 on mesangial cell fibronectin synthesis: increased incorporation into the extracellular matrix and reduced pI but no effect on alternative splicing. Exp Mol Pathol 1993; 59: 211-24.